A Nanobody-on-Quantum Dot Displacement Assay for Rapid and Sensitive Quantification of the Epidermal Growth Factor Receptor (EGFR)

Angew Chem Int Ed Engl. 2022 Aug 15;61(33):e202207797. doi: 10.1002/anie.202207797. Epub 2022 Jul 8.

Abstract

Biosensing approaches that combine small, engineered antibodies (nanobodies) with nanoparticles are often complicated. Here, we show that nanobodies with different C-terminal tags can be efficiently attached to a range of the most widely used biocompatible semiconductor quantum dots (QDs). Direct implementation into simplified assay formats was demonstrated by designing a rapid and wash-free mix-and-measure immunoassay for the epidermal growth factor receptor (EGFR). Terbium complex (Tb)-labeled hexahistidine-tagged nanobodies were specifically displaced from QD surfaces via EGFR-nanobody binding, leading to an EGFR concentration-dependent decrease of the Tb-to-QD Förster resonance energy transfer (FRET) signal. The detection limit of 80±20 pM (16±4 ng mL-1 ) was 3-fold lower than the clinical cut-off concentration for soluble EGFR and up to 10-fold lower compared to conventional sandwich FRET assays that required a pair of different nanobodies.

Keywords: Diagnostics; EGFRvIII; FRET; Lanthanides; Nanoparticles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ErbB Receptors
  • Fluorescence Resonance Energy Transfer
  • Quantum Dots*
  • Single-Domain Antibodies*
  • Terbium

Substances

  • Single-Domain Antibodies
  • Terbium
  • ErbB Receptors